November 22, 2023
(press release)
–
Attachment
We are pleased to invite investors and analysts to participate in a live webinar on
Wednesday, 29 November 2023, highlighting Roche`s digital efforts in the Pharma and Diagnostics value chain, covering the utilization of AI/ML in many aspects of our business and the utilization of advanced data analytics and computational biology in drug discovery.
Speakers
Alan Hippe, Chief Financial and IT Officer Roche
Aviv Regev, Global Head - gRED
Scott Oloff, Global Head - Data & Analytics, pRED
Moritz Hartmann, Global Head of Roche Information Solutions, Roche Diagnostics
Kent Kost, Global Head of Diagnostics Operations, Roche Diagnostics
13:30 - 15:30 CET / 12:30 - 14:30 GMT
7:30 – 9:30 am EST / 4:30 – 6:30 am PST
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 12:30 CET on the day of the event.
> click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via > ir.roche.com
*privacy notice
Best regards,
Bruno Eschli
Head of Investor Relations
Gerard Tobin
Investor Relations Officer
Roche Investor Relations
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.